Half-Yearly Report January-June 2023
Continued strong growth in both enzyme and antibody business April – June 2023 · Net sales totaled SEK 29,463 (21,093) thousand, with a growth rate of 40%. Growth is 30%, adjusted for currency effects. · Operating profit before depreciation and amortization (EBITDA) totaled SEK 7,687 (2,109) thousand. · Operating profit (EBIT) totaled SEK 5,981 (221) thousand. · Profit for the period totaled SEK 15,219 (672) thousand. · Earnings per share totaled SEK 0.23 (0.01). · Comprehensive income for the period totaled SEK 16,843 (811) thousand. · Cash flow from operating